Investigational Drug Information for Huperzine-A
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Huperzine-A?
Huperzine-A is an investigational drug.
There have been 12 clinical trials for Huperzine-A.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Schizophrenia. The leading clinical trial sponsors are Zhijun Bao, National Institute on Drug Abuse (NIDA), and Jiangsu Famous Medical Technology Co., Ltd.
Summary for Huperzine-A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 33 |
Recent Clinical Trials for Huperzine-A
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery | Second Affiliated Hospital of Wenzhou Medical University | N/A |
| Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 |
| Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging | Shanghai Mental Health Center | Phase 4 |
Clinical Trial Summary for Huperzine-A
Top disease conditions for Huperzine-A
Top clinical trial sponsors for Huperzine-A
US Patents for Huperzine-A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
